LIVN · LivaNova PLC
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. LivaNova delivered Q2 2026 revenue of $390.6 million (up 9.8% constant-currency / 10.8% reported) with record adjusted EPS of $1.26, raised full-year 2026 revenue growth outlook to 8%–9% and adjusted EPS to $4.30–$4.40, but lowered adjusted free-cash-flow guidance to $140–$160 million due to higher capex and Thermo Fisher funding.
- + Full-year 2026 revenue guidance raised to 8%–9% (from 7%–8%) constant-currency
- + Cardiopulmonary segment outlook raised to 9.5%–10.5% growth (from 8.5%–9.5%)
- + Epilepsy segment outlook raised to 7%–8% growth (from 6%–7%) on reimbursement and CORE data
- − Full-year 2026 adjusted free-cash-flow guidance lowered to $140–$160 million (from $160–$180 million)
- − Full-year capex raised to $135 million (from $120 million) for capacity expansion and IT
- − OSA PMA supplement timing pushed to between 2H 2026 and 1H 2027 from prior 2H 2026 expectation
- − Adjusted free cash flow of $45.5 million declined modestly YoY on higher capex and working capital
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIVN
this stock
LivaNova PLC
|
$4.22B | +21.4% | +10.7% | 22.6 | 9.8% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIVN | -1.0% | -9.3% | +19.0% | -2.4% | +21.4% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -0.6% | -9.2% | +6.6% | -2.5% | +9.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.